Search results
Showing 16 to 30 of 33 results for acute lymphoblastic leukaemia
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
Awaiting development Reference number: GID-TA11837 Expected publication date: TBC
Discontinued Reference number: GID-TA11181
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Past technology appraisal appeals and decisions
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Discontinued Reference number: GID-TA10316
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 975.
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.